Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05315700 · ClinicalTrials.gov registry record · Phase 1

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

A Phase 1 study of Solid Tumors, sponsored by ORIC Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
350
Enrollment target
20
Study locations

NCT05315700 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by ORIC Pharmaceuticals. The registered enrollment target is 350 participants, above the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05315700, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by ORIC Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
350 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Conditions Studied

Solid Tumors

Interventions

  • DRUG ORIC-114
  • DRUG Chemotherapy drug

Study Locations (20)

California

  • City of Hope - Duarte
  • City of Hope - Huntington Beach
  • City of Hope - Irvine
  • City of Hope - Long Beach
  • University of California, San Francisco - San Francisco

Other

  • Chris O'Brien Lifehouse - Camperdown
  • Peter MacCallum Cancer Centre - Melbourne
  • One Clinical Research, Hollywood Medical Centre - Nedlands

Florida

  • Mayo Clinic - Jacksonville
  • Moffitt Cancer Center - Tampa

Connecticut

  • Yale Cancer Center - New Haven

District of Columbia

  • Georgetown University - Washington D.C.

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2022-03-10
Est. Completion 2027-09
Phase Phase 1

Sponsor

ORIC Pharmaceuticals

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05315700

The ClinicalTrials.gov registry entry for NCT05315700 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target (24% higher). The listed sponsor is ORIC Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which ORIC-114 is the first listed.

NCT05315700 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT05315700 about?

NCT05315700 is a clinical study titled "Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration". The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advance...

What is the current status of trial NCT05315700?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2022-03-10. Estimated completion is 2027-09.

What conditions does trial NCT05315700 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT05315700?

The interventions under investigation include: ORIC-114 (DRUG), Chemotherapy drug (DRUG).

Who is sponsoring clinical trial NCT05315700?

This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05315700 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.